Ponatinib (AP24534) 是一种口服活性的多靶点激酶抑制剂，对 Abl 的 IC50 为 0.37 nM，对 PDGFRα 为 1.1 nM，对 VEGFR2 为 1.5 nM，对 FGFR1 为 2.2 nM，对 Src 为 5.4 nM。

Axitinib是一种多靶点酪氨酸激酶抑制剂，对VEGFR1、VEGFR2、VEGFR3和PDGFRβ的IC50值分别为0.1 nM、0.2 nM、0.1-0.3 nM和1.6 nM。

Nintedanib（BIBF 1120）是一种强效的三重血管激酶抑制剂，对VEGFR1/2/3、FGFR1/2/3和PDGFRα/β的IC50值分别为34 nM、13 nM、13 nM、69 nM、37 nM、108 nM、59 nM和65 nM。

Crenolanib是一种强效且选择性的III类受体酪氨酸激酶FLT3和PDGFRα/β野生型和突变型异构体的抑制剂，Kd值分别为0.74 nM和2.1 nM/3.2 nM。

Telatinib 是一种强效的 VEGFR2/3、c-Kit 和 PDGFRα 抑制剂，IC50 分别为 6 nM/4 nM、1 nM 和 15 nM。

Masitinib is an inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms.

Tivozanib is an inhibitor of VEGFR1, VEGFR2 and VEGFR3 with IC50s of 30 nM, 6.5 nM, 15 nM, respectively. It can also inhibit PDGFR and c-Kit.

Amuvatinib is a potent and multi-targeted inhibitor that inhibits c-Kit, PDGFRα and Flt3 with IC50 of 10, 40 and 81 nM respectively.

CP-673451 is a selective inhibitor of PDGFRα/β with IC50 of 10 nM/1 nM in cell-free assays, exhibits > 450-fold selectivity over other angiogenic receptors, has antiangiogenic and antitumor activity.

Ki8751 is a selective VEGFR2 inhibitor with IC50 of 0.9 nM.

BLU-285 is a potent KIT receptor and PDGFRα dual inhibitor with IC50 of 0.27 and 0.24 nM for KIT (D816V) and PDGFRα (D842V) respectively, developed as a highly targeted therapy for SM.